The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX)

Trial Profile

The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Paroxetine (Primary) ; Telaprevir (Primary)
  • Indications Depressive disorders; Hepatitis C
  • Focus Pharmacokinetics
  • Acronyms ROLEX
  • Most Recent Events

    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 20 Jun 2014 Planned Primary Completion Date is 1 Jul 2014 as reported by ClinicalTrials.gov record.
    • 20 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top